ASCO GU 2019 darolutamide, ARAMIS study darolutamide in non-metastatic castration-resistant prostate (nmCRPC), Karmin Fizazi, MD, the efficacy and safety of ODM-201 in high-risk nmCRPC patients.
— Read on www.urotoday.com/conference-highlights/asco-gu-2019/asco-gu-2019-prostate-cancer/110279-sco-gu-2019-efficacy-and-safety-data-of-the-aramis-study-darolutamide-in-nonmetastatic-castration-resistant-prostate-cancer-patients.html
A New Minimally Invasive Option for the Treatment of BPH